Site Search

... partners are working together to make sure more Minnesotans can benefit from this important testing.   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment for a patient . A “ biomarker ” is a sign of a normal biological process, ... that have been excluded, including communities of color, individuals with lower socioeconomic status, rural communities, and those receiving care in non-academic medical centers are less likely to receive biomarker testing. Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities. Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing ...

... with research focused on the design and implementation of programming to reduce sociocultural and economic barriers that contribute to disparate health outcomes for racial/ethnic minorities and underserved populations, Dr Winkfield’s current responsibilities include collaborating with ... received her MD and PhD degrees at Duke University and completed her training in the Harvard Radiation Oncology Program. She is Professor of Health Policy at Meharry’s new School of Global Health and serves as Associate Director of Community Outreach and Engagement at the Vanderbilt ... to empower the community with knowledge and encourage policymakers to invest in initiatives designed to improve the U.S. healthcare and cancer care delivery systems. In 2021, Dr. Winkfield was appointed to serve a 6-year term on the National Cancer Advisory Board. Karen Winkfield, MD, PhD ...

... What is biomarker testing? Biomarker testing helps get the right treatment to the right patient at the right time. Progress in improving health outcomes increasingly involves the use of precision medicine, which uses information about a person’s own genes or proteins to prevent, ... of a patient’s tissue, blood, or fluid biospecimen for the presence of a biomarker. Biomarker testing is increasingly important for cancer care – and for the treatment of other diseases. Thirty-seven of the 62 oncology drugs launched in the past five years require or recommend ... biomarker testing when medically appropriate. Improving access to biomarker testing and thereby access to targeted therapies will help reduce health disparities and improve outcomes for cancer patients. Expanding access to biomarker testing will also increase patient diversity in clinical ...

... and partners are working together to make sure more Nevadans can benefit from this important testing.   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment for a patient . A “ biomarker ” is a sign of a normal biological process, ... that have been excluded, including communities of color, individuals with lower socioeconomic status, rural communities, and those receiving care in non-academic medical centers are less likely to receive biomarker testing. Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities. Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing ...